Initially approved in 2012, vismodegib is the first FDA-approved pharmacologic agent that targets the Hedgehog signaling pathway (sonic hedgehog, SHH), a pathway involved in many basal cell carcinomas. Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC), accounting for over one-half of all NMSC diagnoses. BCC affects over 3.3 million a year in the United States. Approximately 40% of patients diagnosed with BCC will develop another BCC within five years of the initial diagnosis. Management is primarily with surgical intervention, except in some cases where topical therapy is utilized. Not all patients are suitable candidates for surgery or topical treatment due to locally advanced or metastatic basal cell carcinoma; this is where vismodegib has a place in therapy. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring, of vismodegib so providers can direct patient therapy in cancer treatment where it is indicated as part of the interprofessional team.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/36408
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Complex General Surgical Oncology, Dermatopathology, General Surgery, Internal Medicine, Medical Oncology